Principal Technologies Inc.

Equities

PTEC

CA74260Q1028

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 16:51:50 11/02/2026 GMT			5-day change	1st Jan Change
0.5500 ^CAD	0.00%		0.00%	-8.33%

12-30	Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2025	CI
12-15	Principal Technologies closes private placement financing	RE

Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2025

Published on 12/30/2025 at 10:35 pm GMT

S&P Capital IQ

PRINCIPAL TECHNOLOGIES INC.

0.00%

-0.64%

+0.23%

-0.24%

-0.05%

Principal Technologies Inc. reported earnings results for the first quarter ended October 31, 2025. For the first quarter, the company reported net loss was CAD 0.787798 million compared to CAD 0.561981 million a year ago.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
PRINCIPAL TECHNOLOGIES INC.	0.5500CAD	0.00%	0.00%	21.48M
CANADIAN DOLLAR / JAPANESE YEN	112.1890JPY	-0.64%	-2.24%	-
BRITISH POUND / CANADIAN DOLLAR	1.8533CAD	+0.23%	-0.68%	-
AUSTRALIAN DOLLAR / CANADIAN DOLLAR	0.9646CAD	-0.24%	+0.88%	-
NEW ZEALAND DOLLAR / CANADIAN DOLLAR	0.8204CAD	-0.05%	+0.20%	-

Latest news about Principal Technologies Inc.

12-30	Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2025	CI
12-15	Principal Technologies closes private placement financing	RE
12-14	Principal Technologies Inc. announced that it has received CAD 1.2 million in funding	CI
11-29	Principal Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2025	CI
11-28	Principal Technologies Inc. Auditor Raises 'Going Concern' Doubt	CI
11-28	Principal Technologies Announces Private Placement Financing	MT
11-26	Principal Technologies Inc. announced that it expects to receive CAD 1.2 million in funding	CI
31/10/25	The management of E&E Cro Consulting GmbH agreed to acquire 60% stake in E&E Cro Consulting GmbH from Principal Technologies Inc. in a management buyout transaction.	CI
31/10/25	Principal Technologies Partners With University of Oxford on Thermal Sensor for Cancer Applications	MT
31/10/25	Principal Technologies Inc. Enters into Research and Development Agreement with the University of Oxford	CI
30/07/25	Principal Technologies Inc. announced that it has received CAD 3.456775 million in funding from RLOX Beteiligung GmbH	CI
28/07/25	Principal Technologies announces private placement financing	RE
26/06/25	Principal Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2025	CI
11/05/25	Principal Technologies Inc. announced that it has received CAD 1.03 million in funding	CI
08/05/25	Principal Technologies Inc. announced that it has received CAD 1.03 million in funding	CI
02/05/25	Principal Technologies Announces Private Placement Financing And Grant Of Stock Options	RE
01/05/25	Principal Technologies Inc. announced that it expects to receive CAD 0.25 million in funding	CI
29/04/25	Principal Technologies Provides Update on Financing of Oxford License Agreement	MT
24/04/25	Principal Technologies Inc. announced that it expects to receive CAD 3.744002 million in funding	CI
17/04/25	Principal Technologies to Settle Debt by Issuing Units, Shares	MT
17/04/25	Principal Technologies Announces Debt Settlement Transactions	RE
08/04/25	Principal Technologies Signs Oxford License Agreement	MT
08/04/25	Principal Technologies Announces Oxford Licence Agreement	RE
28/03/25	Principal Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2025	CI
30/12/24	Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2024	CI

Chart Principal Technologies Inc.

Duration

Period

PTEC: Dynamic Chart

Company Profile

Principal Technologies Inc. is a Canada-based company. The Company is engaged in building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential which have intellectual property capable of enhancing medical treatment quality, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. It operates in one operational segment, being its operations in healthcare technology, including the project management of international scale clinical studies primarily related to medical device technologies. The Company's subsidiaries include Principal Technologies Capital Management GmbH and E&E CRO Consulting GmbH.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-26 - Q2 2026 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data